Part A: Safusidenib Erbumine Clinical Trials (2026): 2 Studies for Glioma & Astrocytoma, IDH-Mutant, Grade 2
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 Part A: Safusidenib Erbumine clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Glioma & Astrocytoma, IDH-Mutant, Grade 2) and 379 total planned enrollment. 1 Phase 3 Part A: Safusidenib Erbumine trial are listed. 1 Part A: Safusidenib Erbumine clinical trial is actively recruiting at 36 U.S. sites across 23 states. Most recent activity: NCT05303519 (Dec 2030).
Where to Participate: All Part A: Safusidenib Erbumine Trial Sites in the U.S. (36 sites across 23 states)
Every actively recruiting Part A: Safusidenib Erbuminetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama | Birmingham35294 | NCT05303519 | Map |
| AZ | Mayo Clinic - Arizona | Phoenix85013 | NCT05303519 | Map |
| AZ | St. Joseph's Hospital and Medical Center | Phoenix85013 | NCT05303519 | Map |
| CA | University of California, Los Angeles | Los Angeles90095 | NCT05303519 | Map |
| CA | Hoag Memorial Hospital Presbyterian | Newport Beach92663 | NCT05303519 | Map |
| CA | Stanford University | Palo Alto94304 | NCT05303519 | Map |
| CA | University of California | San Francisco94143 | NCT05303519 | Map |
| CO | University of Colorado Health Cancer Care | Aurora80045 | NCT05303519 | Map |
| CT | Yale University | New Haven06510 | NCT05303519 | Map |
| FL | University of Florida Health | Gainesville32608 | NCT05303519 | Map |
| FL | Mayo Clinic - Florida | Jacksonville32224 | NCT05303519 | Map |
| FL | University of Miami Health | Miami33136 | NCT05303519 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT05303519 | Map |
| IN | Indiana University | Indianapolis46202 | NCT05303519 | Map |
| KS | University of Kansas Medical Center | Kansas City66160 | NCT05303519 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05303519 | Map |
| MA | Massachusetts General Hospital | Boston02214 | NCT05303519 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05303519 | Map |
| MN | Mayo Clinic - Rochester | Rochester55905 | NCT05303519 | Map |
| MO | Washington University | St Louis63110 | NCT05303519 | Map |
| MT | Billings Clinic | Billings59101 | NCT05303519 | Map |
| NJ | Rutgers Cancer Institute | New Brunswick08901 | NCT05303519 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT05303519 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05303519 | Map |
| NY | NYU Langone Health | New York10016 | NCT05303519 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT05303519 | Map |
| NC | Duke Cancer Institute | Durham27710 | NCT05303519 | Map |
| OH | Cleveland Clinic | Cleveland44106 | NCT05303519 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT05303519 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT05303519 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT05303519 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT05303519 | Map |
| UT | Huntsman Cancer Insititute, University of Utah | Salt Lake City84112 | NCT05303519 | Map |
| VA | UVA Health, Emily Couric Clinical Cancer Cente | Charlottesville22903 | NCT05303519 | Map |
| WA | Fred Hutch Cancer Center | Seattle98195 | NCT05303519 | Map |
| WI | University of Wisconsin Health | Madison53792 | NCT05303519 | Map |
Part A: Safusidenib Erbumine clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| Early P1 | 1 | 1 | |
| P3 | 1 | 1 |
Recruiting Part A: Safusidenib Erbumine clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05303519 | SIGMASIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | P3 | Glioma | 365 | Jun 2023 |
Part A: Safusidenib Erbumine pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SIGMA | NCT05303519 | P3 | recruiting | Glioma | 365 | — |
All Part A: Safusidenib Erbumine trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05303519 | SIGMA | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | P3 | recruiting | 365 | Nuvation Bio Inc. | Jun 2023 |
| NCT05577416 | AB-218-IIT-201 | A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma | Early P1 | completed | 14 | Melbourne Health | Oct 2022 |
Part A: Safusidenib Erbumine clinical trials: frequently asked questions
- How many Part A: Safusidenib Erbumine clinical trials are there?
- 2 Part A: Safusidenib Erbumine clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are Part A: Safusidenib Erbumine clinical trials recruiting in 2026?
- Yes — 1 Part A: Safusidenib Erbumine trial is actively recruiting in 2026, with 36 U.S. sites across 23 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Part A: Safusidenib Erbumine being studied for?
- Part A: Safusidenib Erbumine is being studied for Glioma, Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, IDH1-mutant Glioma and 3 more. The trials are grouped by indication on this page.
- What phase is Part A: Safusidenib Erbumine in?
- Part A: Safusidenib Erbumine clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Part A: Safusidenib Erbumine clinical trials?
- The lead sponsor across the most Part A: Safusidenib Erbumine trials is Melbourne Health, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Part A: Safusidenib Erbumineas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: